RecruitingPhase 3NCT07026474
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universität des Saarlandes
- Intervention
- radiotherapy(other)
- Enrollment
- 214 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (18)
- Klinikum Chemnitz gGmbH, Klinik für Radioonkologie, Chemnitz, Germany
- Klinikum Darmstadt GmbH, Institut für Radioonkologie und Strahlentherapie, Darmstadt, Germany
- Gemeinschaftspraxis Hämatologie-Onkologie Dresden, Dresden, Germany
- Uniklinikum Erlangen, Strahlenklinik, Erlangen, Germany
- Universitätsmedizin Frankfurt, Klinik für Strahlentherapie und Onkologie, Frankfurt am Main, Germany
- UKGM Gießen, Klinik für Strahlentherapie, Giessen, Germany
- Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie; II. Medizinische Klinik und Poliklinik, Hamburg, Germany
- Medizinische Hochschule Hannover (MHH), Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hanover, Germany
- Marien Hospital Herne, Klinik für Strahlentherapie und Radio-Onkologie, Herne, Germany
- Universitätsklinikum des Saarlandes, Klinik für Strahlentherapie und Radioonkologie, Homburg, Germany
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Radioonkologie der Strahlentherapie, Mainz, Germany
- Universitätsklinikum Münster, Klinik für Strahlentherapie - Radioonkologie, Münster, Germany
- Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie, Regensburg, Germany
- CaritasKlinikum Saarbrücken St. Theresia, Klinik für Radioonkologie und Strahlentherapie, Saarbrücken, Germany
- Klinikum St.-Elisabeth Straubing GmbH, Klinik für Hals-Nasen-Ohren-Heilkunde, Straubing, Germany
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07026474 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
- RECRUITINGPHASE2NCT06856213Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
See all trials for Squamous cell carcinoma of head and neck →